To JN-International Medical Corporation
A U.S. based private biopharmaceutical corporation has been developing vaccines for infectious disease and neurological disorders. Emphasis on our 20-years of basic research combined with an applied focus on specific medical needs was instrumental to success and growth of this corporation. As vaccine research and development took exciting new directions through emerging knowledge about "cure-unknown" diseases, JN continued to press forward. Even as many others abandoned vaccine research, JN remained on the leading edge in vaccine development. In fact, “JN has played a leading role in the inventing of some of the most signiﬁcant vaccine advances over the last two decades, and our commitment and excitement about vaccines today are stronger than ever.
Do You Know?
JN is the 3rd BioPharma to develop patented Meningococcal meningitis serogroups A/C/Y/W135 diphtheria toxoid conjugate vaccine (NmVac-4DT).
"Promising new studies attempt to perfect Genital Herpes and Meningitis serogroup ‘B’ vaccines."
Inc 5000 Fastest Growing Company.
What Special of this vaccine?
“NmVac-4 A/C/Y/W-135 DT conjugate vaccine is among the most complex biotech or biologic products. It’s a combination vaccine that contains four 4 different vaccines in one and can be used with any combination by the geographic prevalence of the disease causing serogroup A, C, Y & W-135” and it is suitable for all ages.
The only true Halal Vaccine
صحيح قاح التهاب السحايا الحلال للحج والعمرة
“NmVac-4 A/C/Y/W-135 DT conjugate vaccine is made with 100% vegetable media with no animal components used in upstream and downstream process. The process and media have been patented”. The vaccine is suitable for millions of Muslims worldwide and other religions. Most importantly the vaccine is free from Bovine spongiform encephalopathy (BSE), commonly known as Mad Cow disease.
NEWS & EVENTS
Immunogenicity and Safety of JN's serogroups A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac-4-A/C/Y/W135 DT™) Results Published Clinical Trials.govRead more...
Immunogenicity and Safety of JN's serogroups A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (NmVac-4-A/C/Y/W135 DT™) planned to conduct in 20 centers in the United States by IRC Clinics in Maryland Read more...